Histone deacetylase (HDAC) inhibitors are emerging as a new class of targeted cancer chemotherapeutics. Several HDAC inhibitors are currently in clinical trials and promising anticancer effects at well-tolerated doses have been observed for both hematologic and solid cancers. HDAC inhibitors have been shown to induce cell-cycle and growth arrest, differentiation and in certain cases apoptosis in cell cultures and in vivo. However, it is known that these compounds induce varying responses in different cells and biological settings, and identifying their precise mechanisms of action is an area of great interest. Important findings are continually expanding our understanding of the cellular effects of HDAC inhibitors and recent studies will be briefly outlined in this review. In addition to their intrinsic anticancer properties, numerous studies have demonstrated that HDAC inhibitors can modulate cellular responses to other cytotoxic modalities including ionizing radiation, ultraviolet radiation and chemotherapeutic drugs. Hence, there is a growing interest in potential clinical use of HDAC inhibitors in combination with conventional cancer therapies. In this review, the interaction of HDAC inhibitors with other anticancer agents is discussed. The focus of the article is on the different mechanisms by which HDAC inhibitors enhance the sensitivity of cells to the effects of ionizing radiation.
Introduction
It is well established that post-translational modifications of core histones play a major role in modeling higher-order chromatin structure and controlling gene transcription. Histone proteins organize the DNA into nucleosomes that are the basic repeating units of chromatin. In brief, nucleosomes consist of about 146 base pairs of DNA tightly wrapped around a histone octamer. The octameric histone structure contains two each of the core histones, H2A, H2B, H3 and H4 (Jenuwein and Allis, 2001; Zhang and Reinberg, 2001; Spotswood and Turner, 2002) . A fundamental epigenetic mechanism for remodeling chromatin architecture and regulating gene expression involves the reversible post-translational modification of the terminal tails of the core histones. These include acetylation and deacetylation of lysines, methylation of lysine and arginine residues, phosphorylation of serines and ubiquination and sumoylation of lysines (Jenuwein and Allis, 2001; Fischle et al., 2003) . It has been postulated that combinations of these post-translational modifications represent an epigenetic code that is recognized by non-histone proteins that are involved in regulating gene expression (Jenuwein and Allis, 2001; Zhang and Reinberg, 2001; Spotswood and Turner, 2002; Fischle et al., 2003) .
The most well-characterized post-translational histone modifications are acetylation and deacetylation of the amino-terminal tails of specific lysine residues. The acetylation status of the core histones is controlled by the opposing actions of two classes of enzymes, histone acetyltransferases (HATs) and histone deacetylases (HDACs) (Struhl, 1998; Gregory et al., 2001; Thiagalingam et al., 2003) . The HATs catalyse the acetylation of lysines in core histones. This results in neutralization of the positive charges on histones and decreases their interaction with the negatively charged DNA. The effect is a 'relaxed' or more open, transcriptionally active, chromatin conformation (Marks et al., 2000) . The HDACs catalyse the removal of acetyl groups from lysine residues resulting in a more compacted, transcriptionally repressed, chromatin structure (Marks et al., 2001) . Overall, it is proposed that acetylation levels regulate gene transcription by controlling the accessibility of transcription factors to DNA (Grunstein, 1997) . Indeed, HAT and HDAC activity has been identified within transcriptional coactivators and corepressors, respectively, providing strong evidence of the functional connection between histone acetylation and transcription (Brownell et al., 1996; Alland et al., 1997) .
Aberrant HAT or HDAC activity has been observed in numerous cancers. Oncogenesis has been associated with HAT inactivation and evidence indicates that abnormal HDAC activity results in transcriptional repression of specific genes that promote tumor suppression, which is considered to be a critical event contributing to tumor formation (Petrij et al., 1995; Johnstone, 2002) . From this background, the idea that inhibition of HDAC activity may be a useful cancer therapy approach emerged and several HDAC inhibitors have been developed as potential targeted cancer therapeutics. Importantly, several HDAC inhibitor compounds have advanced to clinical trials and some are exhibiting promising anticancer effects (Kelly et al., 2002) . In this review, different classes of HDAC inhibitors and their proposed molecular mechanisms of action are outlined.
Given that HDAC inhibitors disrupt critical cellular processes, it was conceivable that combinations of these compounds with other cancer therapies may provide a therapeutic benefit. Obviously, an advantage could be obtained simply by an additive effect because of the different cytotoxic mechanisms associated with each treatment modality. However, it is also evident that a synergistic effect between HDAC inhibitors and other cytotoxic-inducing modalities may be possible as consequence of the ability of HDAC inhibitors to modulate chromatin confirmation per se, as well as to regulate gene expression by histone acetylation. Indeed, a number of studies have shown that HDAC inhibitors can modulate cellular responses to other conventional therapies including ionizing radiation (Chung et al., 2000) , ultraviolet (UV) radiation (Kim et al., 2005) and chemotherapeutic drugs (Kim et al., 2003) . In this review, the molecular mechanisms underlying the interaction of combinations of HDAC inhibitors with other anticancer agents is discussed. The focus is on the mechanisms by which HDAC inhibitors modulate the sensitivity of cells to the effects of ionizing radiation, and the potential for clinical application of HDAC inhibitors in combination with radiation therapy is explored.
Cellular effects of HDAC inhibitors
The 18 HDAC enzymes identified in humans have been divided into three classes on the basis of structural homology with three distinct yeast HDACs (de Ruijter et al., 2003) . Class I enzymes that include HDACs 1, 2, 3 and 8 are related to yeast reduced potassium dependency 3 deacetylase and share homology in the catalytic sites (Grozinger and Schreiber, 2002; de Ruijter et al., 2003) . Class II consists of HDACs 4, 5, 6 and 9 (Grozinger and Schreiber, 2002; de Ruijter et al., 2003) . These are larger enzymes (between 120 and 135 kDa) than class I HDACs (between 22 and 55 kDa) and are related to yeast histone deacetylase 1. HDACs 6 and 10 contain two catalytic sites that are homologous with the class II catalytic site. The catalytic region of HDAC 11 contains conserved residues that are shared by both class I and class II enzymes, and a recent report defined this deacetylase as a class IV enzyme (Gregoretti et al., 2004) . The third class (class III) of HDACs is the silencing information regulator 2 (Sir2) family of deacetylases (Grozinger and Schreiber, 2002) . Deacetylases in this class have a unique catalytic mechanism that requires the cofactor NAD þ and it appears that histones are not their primary substrates (Grozinger and Schreiber, 2002) . The deacetylase activity of class III enzymes is virtually unaffected by HDAC inhibitors, including compounds that are currently in clinical trials, which inhibit class I and II HDACs (Grozinger and Schreiber, 2002; de Ruijter et al., 2003; Gregoretti et al., 2004; Taddei et al., 2005) .
With respect to the development of specific HDAC inhibitors, it is important to consider that different HDACs have varying expression patterns in different cell types and diverse functions. For example, class I HDACs are expressed in most cell types and are found almost exclusively in the nucleus de Ruijter et al., 2003) . In contrast, the expression of class II HDACs is more restricted, and it has been identified that they shuttle between the nucleus and cytoplasm in response to different cellular signals (Turner, 2002) . Although the different functions of HDAC isoforms have not yet completely been deciphered, it is evident that there are many differences and individual HDAC isoforms are emerging as potential therapeutic targets. The classical HDAC inhibitors, such as Trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA) and related compounds, interact directly with the HDAC homologue structure which is generally conserved in all HDACs (Finnin et al., 1999) . However, there is divergence in the residues surrounding the HDAC homologue structure in different HDACs providing an opportunity for the development of isoform-specific HDAC inhibitors (Finnin et al., 1999) . Given these considerations, the identification or synthesis of HDAC inhibitors with specificity for cell-types and for specific HDAC classes or isoforms is an area of intense research.
There are several classes of compounds that have been shown to inhibit the activity of HDACs. The classical HDAC inhibitor, TSA, is a member of the hydroxamic acid class and has been characterized extensively in vitro (Yoshida et al., 1990) . It is a Streptomyces metabolite that was originally developed as an antifungal agent. Numerous studies have demonstrated that TSA is an extremely potent inhibitor of HDAC activity at nanomolar concentrations. It has been suggested that it mediates chromatin remodeling and gene expression by interfering with the catalytic reaction -removal of acetyl groups from the lysine residues of core histones -which is catalysed by HDAC enzymes (Finnin et al., 1999; Marks et al., 2004) . Specifically, TSA is thought to inhibit HDACs by chelating a zinc ion in the active site pocket through its hydroxamic acid group. The X-ray crystal structure of the interaction of another hydroxamic acid, SAHA, with HDAC has also been solved (Finnin et al., 1999) . Similarly, it was shown that the interaction of the hydroxamic acid group with the zinc at the catalytic site is a pre-requisite for the HDAC inhibition activity of SAHA (Finnin et al., 1999) . This hydroxamate is also a potent HDAC inhibitor possessing activity at nanomolar concentrations (Richon et al., 1998) . A separate class of HDAC inhibitors is the cyclic tetrapeptide group, which includes depsipeptide and apicidin, that are also active at nanomolar concentrations (Furumai et al., 2001 (Furumai et al., , 2002 Singh et al., 2002) . The benzamide (e.g. MS-275 and CI-994) (Saito et al., 1999; Prakash et al., 2001 ) and electrophilic ketone (e.g. trifluoromethyl ketones and a-ketoamides) (Frey et al., 2002) classes of HDAC inhibitors are less potent than hydroxamates and cyclic tetrapeptides, exhibiting HDAC inhibition activity in the micromolar concentration range. The least potent class of HDAC inhibitors is the aliphatic acid group of compounds that are effective inhibitors of HDAC activity at millimolar concentrations (Phiel et al., 2001; Boivin et al., 2002) . However, this class includes phenylbutyrate which has advance to clinical trials and valproic acid which is a well-established therapeutic for a variety of seizure disorders as well as bipolar (manic depressive) illness and is well tolerated (Phiel et al., 2001; Bowden and Singh, 2005) .
HDAC inhibitors induce differentiation, cell growth and cell-cycle arrest, and in certain cases apoptosis in numerous transformed cell lines in culture and in tumor cells in animal model systems (Kelly et al., 2002; Marks et al., 2004) . Furthermore, HDAC inhibitors have been shown to alter the transcription of critical regulators of invasion and to inhibit angiogenesis in vivo (Kim et al., 2001; Marks et al., 2004; Mitsiades et al., 2004) . Multiple mechanisms by which HDAC inhibitors induce anticancer effects have been identified to date and the intense research in this area is continually highlighting the complex nature of their activity. It is evident that the anticancer effects of HDAC inhibitors are caused in part by the accumulation of acetylated histones that results in the altered transcription of a finite number of genes (Jenuwein and Allis, 2001; Zhang and Reinberg, 2001; Butler et al., 2002; Spotswood and Turner, 2002; Marks et al., 2004) . Alternatively, HDAC inhibitors alter gene transcription by modulating the acetylation status of transcription regulating proteins, such as NK-kB, GATA1, E2F-1 and MyoD or components of the transcriptional machinery (Kouzarides, 2000; Lagger et al., 2002; Dokmanovic and Marks, 2005) . The net result is the activation and repression of specific genes resulting in antiproliferative or proapoptotic effects. HDAC inhibitors can also alter the activity of numerous other proteins that are subject to reversible acetylation on lysine residues. For example, key regulators of signaling cascades such as pRB and p53, certain hormone receptors including glucocorticoid and thyroid receptors, the chaperone protein HSP90 which is involved in apoptotic pathways and the retinoblastoma tumor suppressor protein have been shown to be altered by HDAC inhibitors (Kouzarides, 1999; Lagger et al., 2002; Johnstone and Licht, 2003; Di Gennaro et al., 2004; Marks et al., 2004) .
Several HDAC inhibitors are currently in clinical trials and promising anticancer effects at well-tolerated doses have been observed in phase I and II trials. The initial clinical findings with compounds such as sodium butyrate (Kruh, 1982; Miller et al., 1987; Perrine et al., 1993) that has a very short half-life in vivo and phenylacetate (Chang et al., 1999) , which only produced modest anticancer effects and significant toxicities, were discouraging. Similarly, TSA which is associated with excessive toxicity and is unstable in vivo has limited clinical applicability (Jung, 2001; Hess-Stumpp, 2005) . However, other hydroxamic acid derivatives including SAHA and pyroxamide have completed phase I trials and are progressing further in clinical trials (Kelly et al., 2002 (Kelly et al., , 2003 Kelly and Marks, 2005) . Results from phase I trials have shown that intravenous SAHA formulations are safe and can inhibit HDAC activity in malignant and normal cells (Kelly et al., 2002 (Kelly et al., , 2003 Kelly and Marks, 2005) . Importantly, SAHA was shown to possess anticancer activity in a broad range of hematologic and solid cancers. Furthermore, an oral formulation of SAHA has favorable bioavailability and pharmacokinetic profiles (Kelly and Marks, 2005) . Numerous phase II trials with SAHA are currently ongoing and preliminary findings in patients with head and neck cancers and T-cell lymphomas are promising. In addition, valproic acid, which has been used extensively in the clinic and has a favorable toxicity profile, is currently being investigated in clinical trials as an anticancer agent (Blaheta et al., 2005) . Depsipeptide is another notable HDAC inhibitor that is currently in clinical trials. Promising results in phase I trials with depsipeptide in patients with T-cell lymphoma have prompted phase II studies that are currently in progress (Piekarz and Bates, 2004; .
In addition to possessing intrinsic anticancer activity, HDAC inhibitors have been identified to be additive or synergistic with other potential cancer therapeutics including flavopiridol, fludarabine, imatinib, proteosome inhibitors, antiangiogenic agents and all-transretinoic acid (Yoshida et al., 2003; Marks et al., 2004; Drummond et al., 2005; Kelly and Marks, 2005; Marks and Jiang, 2005) . The findings from one particular study in which inhibition of HDAC was shown to increase the cytotoxicity to anticancer drugs targeting DNA suggested that altering chromatin structure to a more open conformation and subsequent changes in cellular metabolism by histone acetylation were the important mechanisms for a synergistic effect (Kim et al., 2003) . Numerous subsequent studies have also demonstrated similar synergistic effects providing a rationale for the potential clinical application of combinations of HDAC inhibitors and conventional chemotherapeutics such as doxorubicin (Louis et al., 2005; Tabe et al., 2005) . Similarly, a recent study has identified that pretreatment of cells with TSA before irradiation with UV light increases the UV-mediated cytotoxicity by more than threefold (Kim et al., 2005) . It was concluded that altered chromatin structure and p53 activity caused by HDAC inhibition contributed to the synergistic effect (Kim et al., 2005) . One of the most extensively investigated combinations, which will be the focus of the remaining of the article, is that of HDAC inhibitors and ionizing radiation.
Mechanisms of HDAC inhibitor-mediated enhanced radiation sensitivity
Given the widespread use of radiation therapy in the management of cancer, there has been a longstanding interest in the development of compounds that can modulate cellular responses to ionizing radiation. Studies in the 1980s demonstrated that relatively nontoxic concentrations of the short-chain fatty acid, sodium butyrate enhance the radiation sensitivity of colon cells in vitro (Arundel et al., 1985; Arundel and Leith, 1987; Leith, 1988) . Apart from a subsequent study in which sodium butyrate was shown to enhance the radiation sensitivity of nasopharyngeal cells in culture, research in this area was not pursued presumably because of the limited clinical applicability of the HDAC inhibitor (Chung et al., 2000) . Furthermore, the early findings with combinations of sodium butyrate and radiation were not extended to other HDAC inhibitors until recent years. A study which demonstrated that TSA enhances the radiation sensitivity of cultured human colon carcinoma cells to the effects of g-rays as a result of altering the conformation of chromatin (although the effect was not directly linked with histone hyperacetylation), re-ignited the interest in potential combinations of HDAC inhibitors with ionizing radiation (Biade et al., 2001 ). There are now more than a dozen articles describing the radiation sensitizing properties of a number of HDAC inhibitors in various cell lines and in tumor cells in vivo, and molecular mechanisms underlying this effect are beginning to be characterized.
Ionizing radiation induces DNA damage and it is generally accepted that double strand breaks (DSBs) are the most severe type of lesion with respect to cell survival and preservation of genomic integrity. A DSB is defined as two simultaneous nicks in opposite strands of the DNA helix. A requirement for DSB formation is that the two nicks are in sufficiently close proximity to one another (o12 base pairs) that base-pairing and chromatin structure are unable to maintain the broken DNA ends juxtaposed. Although cells are able to adapt to low level of irreparable DNA damage, only a single DSB is potentially cytotoxic or in some cell types can induce apoptosis (Lee et al., 1998; Rich et al., 2000; Khanna and Jackson, 2001 ). The main cellular responses to DSBs include cell-cycle regulation, DSB repair, transcriptional and post-transcriptional regulation of relevant genes (including those associated with repair), and in certain cases induction of apoptosis. The cellular response to DSBs has been considered as a classical signal-transduction cascade (Richardson and Jasin, 2000; Ferguson and Alt, 2001) . In other words, DSBs (signals) are detected by sensors that activate protein kinase (transduction) cascades resulting in amplification and diversification of the signal through a series of downstream effector molecules (Richardson and Jasin, 2000) . The overall fate -survival or death -of an irradiated cell is dependent upon the type and level of DNA damage. Given these considerations, several mechanisms for a beneficial outcome from a combination of HDAC inhibitors and radiation have been proposed. As mentioned earlier, there could be an additive effect because of the different cytotoxic mechanisms associated with each modality or a synergistic effect may be a consequence of the ability of HDAC inhibitors to modulate chromatin structure and to regulate gene expression by histone acetylation (Chinnaiyan et al., 2005) .
Numerous studies have shown that HDAC inhibitors can enhance the radiation sensitivity of various cell-lines in culture. Classical molecules such as sodium butyrate (Arundel et al., 1985; Arundel and Leith, 1987; Leith, 1988; Chung et al., 2000; Munshi et al., 2005) , phenyl butyrate (Munshi et al., 2005) , tributyrin (Munshi et al., 2005) (Zhang et al., 2004a) and numerous hydroxamic acid analogues such as M344 (Zhang et al., 2004b; Jung et al., 2005) , have been investigated for their radiation sensitizing properties in vitro. The common theme is a synergistic effect following treatment of cells with HDAC inhibitors and subsequent irradiation. Mechanisms including modulation of cellcycle regulation, particularly G1-phase arrest, inhibition of DNA synthesis and apoptosis, have been identified to explain this phenomenon (Zhang et al., 2004b; Karagiannis et al., 2005; Nome et al., 2005) . Clearly these are important mechanisms underlying radiation sensitization by HDAC inhibitors at relatively high doses. However, it has been shown that HDAC inhibitors can modulate the sensitivity of cells to ionizing radiation even at relatively low concentrations, that are sufficient to alter histone acetylation status but are nontoxic and do not induce cell-cycle arrest. The ability of HDAC inhibitors to modulate chromatin architecture, to interact with critical signal transduction proteins involved in DNA damage response pathways and to regulate transcription, particularly of key genes involved in the DNA DSB repair pathway, have been proposed to account for the synergistic effect (Camphausen et al., 2004a, b; Kim et al., 2004; Zhang et al., 2004a; Jung et al., 2005; Munshi et al., 2005) .
Although precise mechanisms are not yet known, various studies have established a connection between HDAC inhibition and proteins involved in signal cascades in response to DNA damage. To discuss this relationship it is important to briefly consider elements of DNA DSB repair pathways. The protein kinase, ataxia telangiectasia mutated protein (ATM) is a critical component of the DSB signaling cascade in mammalian cells (Cliby et al., 1998; Kastan et al., 2000; Abraham, 2001) . It is a member of the phosphatidylinositol 3-kinase-like kinase (PIKK) family, which phosphorylate target proteins on serine or threonine followed by glutamine residues (Kim ST et al., 1999; Durocher and Jackson, 2001) . The current paradigm suggests that ATM is activated following DSB-induced changes in chromatin structure which are recognized by sensor proteins including 53BP1, a DNA damage checkpoint protein conserved in all eukaryotes (Zgheib et al., 2005) . Following activation ATM rapidly phosphorylates downstream substrates that are important in DSB response pathways including p53, which has key roles in cell-cycle control and apoptosis (Figure 1) , MDM2, CHK1 and CHK2 which are involved in cell-cycle regulation, and BRCA1 and NBS1 which are important in DSB repair (Rotman and Shiloh, 1999; Khanna, 2000; Jackson, 2002) .
It has been shown using human fibroblasts that ATM interacts with HDAC1 both in vitro and in vivo (Kim GD et al., 1999; Ju and Muller, 2003) . Importantly, the findings indicated that ionizing radiation enhances ATM-associated HDAC activity suggesting that HDACs may have a critical role in ATM signaling in response to DNA damage (Kim GD et al., 1999) . The fact that this study demonstrated that TSA inhibits this ATM-associated HDAC activity, provides an insight into a possible mechanism by which HDAC inhibitors may enhance the radiation sensitivity of cells (Kim GD et al., 1999) .
Also, altered gene expression or acetylation status of p53 resulting from HDAC inhibition may confer a radiosensitizing effect. The p53 gene is negatively regulated by HDACs and the protein is a known substrate for HATs and HDACs (Sakaguchi et al., 1998; Luo et al., 2000) . Indeed, in response to DNA damage p53 is acetylated at lysine residues in the C-terminal region by the HATs, p300 and PCAF which is thoughtalong with phosphorylation -to stabilize the molecule and it is accumulated in the nucleus where it regulates transcription (Sakaguchi et al., 1998; Juan et al., 2000; Luo et al., 2000) . Among numerous other functions, activated p53 induces transcription of a series of proapoptotic Bcl-2 family members (Oda et al., 2000; Nakano and Vousden, 2001 ). Because expression of p53 could be regulated by HDACs and the stability and activity of p53 is modulated in part by its acetylation status, it is conceivable that HDAC inhibitors may sensitize cells to the effects of radiation by modulating p53. However, it should be noted that HDAC inhibitors have been shown to enhance the radiation sensitivity of cells regardless of their p53 expression status (Zhang et al., 2004a) .
Another DNA repair-related mechanism that could account for the synergistic effect of HDAC inhibitors with radiation may involve HDAC4. The DNA damage sensor protein 53BP1 has been shown to colocalize with HDAC4 in DNA damage-induced nuclear foci and cells with silenced HDAC4 exhibit marked radiosensitivity (Kao et al., 2003; Zgheib et al., 2005) . This implies a role for HDAC4 in DNA repair pathways and provides evidence for another mechanism by which HDAC inhibitors could modulate cellular responses to radiation.
DSBs are repaired in mammalian cells predominantly by either homologous recombination (HR) or nonhomologous end-joining (NHEJ) (Figure 2 ). The HR pathway essentially involves copying the missing information from an undamaged homologous chromosome by a process that relies on extensive sequence homology between the recombining ends (Jackson, 2002) . Genetic analysis of Sacchoromyces cerevisiae suggest that proteins coded by the Rad52 epistasis group of genes -Rad50, Rad51, Rad52, Rad54, Rad55, Rad57, Rad59, Mre11 and Xrs2 -are important in HR (Jackson, 2001 (Jackson, , 2002 Khanna and Jackson, 2001) . In contrast to HR, NHEJ does not rely on an undamaged Figure 1 Schematic representation of cellular responses to DNA damage. DSB signaling pathway can be initiated by ionizing radiation causing modifications to chromatin components such as gH2AX, recruitment of 53BP1 protein and activation of the ATM/ ATM-and Rad3-related (ATR) protein kinases. Central to the mechanism of damage sensing is phosphorylation of p53 and changes to cell cycle control and apoptosis. DSB, double strand break; ATM, ataxia telangiectasia mutated protein. Figure 2 Schematic representation of DNA repair mechanisms in response to DNA damage. DSBs are repaired by one of two mechanisms; homologous recombination, which is dependent on sequence homology for repair, and non-homologous end-joining, which is dependent on binding of Ku heterodimers to damaged sites and recruitment of DNA-PKCs, ATM-and Rad3-related (ATR) and DNA ligation complex. DSB, double strand break; PKC, protein kinase C.
DNA molecule and does not require extensive sequence homology. In the NHEJ pathway, the Ku70/Ku86 (Ku86 is also known as Ku80) heterodimer is the first protein to bind to the broken DNA ends at the site of DSBs (Mimori and Hardin, 1986; de Vries et al., 1989; Falzon et al., 1993) . Binding of Ku to broken DNA termini recruits another PIKK family member, known as the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) (Chiu et al., 1998; Hammarsten and Chu, 1998; West et al., 1998) . The DNA-PKcs form a complex with the specific nuclease, Artemis which resects the DNA termini (Jeggo and O'Neill, 2002; Lieber et al., 2003; Rooney et al., 2003) . Following assembly of the DNA-Ku-DNA-PKcs complex and DNA end processing, the DNA termini are ligated by the XRCC4-DNA-ligase-IV complex (Teo and Jackson, 1997; Wilson et al., 1997) . Results from recent studies provide direct evidence that a mechanism underlying the synergistic effect of HDAC inhibitors and radiation involves suppression of DNA repair. For example, it has been shown that the radiation-induced increase in Rad51 and DNA-PKcs expression is markedly attenuated by pretreatment of a human prostate cancer cell-line with SAHA (Chinnaiyan et al., 2005) . Similarly, another study has demonstrated that sodium butyrate decreases the expression of critical DNA repair proteins Ku70, Ku86 and DNA-PKcs in two melanoma cell-lines (Munshi et al., 2005) .
Phosphorylation of H2AX to form g-H2AX is one of the earliest events following the induction of DSBs (Rogakou et al., 1998 (Rogakou et al., , 1999 . Nuclear g-H2AX foci extend over a megabase range of chromatin from the site of the DSB, and g-H2AX expression has been used as a sensitive marker of ionizing radiation-induced DSBs (Paull et al., 2000; Celeste et al., 2003; Olive and Banath, 2004) . It is established that the g-H2AX form of the histone has an important role in recruiting repair factors to nuclear foci following induction of DSBs (Paull et al., 2000; Celeste et al., 2003; Olive and Banath, 2004) . Recent studies have shown that incubation of cells with HDAC inhibitors including MS-275 and sodium butyrate, results in prolonged expression of induced g-H2AX foci (Camphausen et al., 2004a; Munshi et al., 2005) . These findings indicate that HDAC inhibitor-mediated radiosensitization is associated with a decrease in the repair of DSBs. Furthermore, a recent study using TSA demonstrated an increase in the number of radiationinduced g-H2AX foci, suggesting that the change in chromatin structure caused by histone hyperacetylation results in an increase in the number of DSBs (Karagiannis et al., 2005) .
Regarding potential clinical application of combinations of HDAC inhibitors and radiation, a recent study with valproic acid is important (Camphausen et al., 2005) . As discussed earlier, valproic acid has been used extensively in the clinic for a variety of seizure disorders as well as bipolar (manic depressive) illness (Bowden and Singh, 2005) . It has broad-spectrum anticonvulsant activity, good oral bioavailability and a favorable toxicity profile (Snead and Miles, 1985; Loscher, 1999; Perucca, 2002) . In this particular study, the effects of valproic acid on cancer cell radiosensitivity were investigated given the recent findings that the compound is an effective inhibitor of HDAC activity (Gurvich et al., 2004) . The results indicated that valproic acid sensitized two human glioma cell-lines in culture to the effects of X-rays (Camphausen et al., 2005) . The study was extended to a xenograft animal model system using human glioma cells, which involved intraperitoneal administration of valproic acid followed by specific irradiation of the tumor. The combination of valproic acid and radiation inhibited tumor growth more than radiation alone and controls. Treatment with valproic acid before irradiation resulted in a decrease of the tumor volume by a factor of about 1.6 compared to radiation alone (Camphausen et al., 2005) . Importantly, by analysis of histone acetylation status and gH2AX expression, the radiation sensitizing effects of valproic acid were correlated with HDAC inhibition in both the in vitro and in vivo model systems (Camphausen et al., 2005) . Similarly, animal studies have been performed with MS-275 which has been shown to possess HDAC inhibition activity in vivo (Camphausen et al., 2004b) . The findings indicated that combinations of MS-275 and radiation inhibited tumor growth more than radiation alone or controls in mice bearing human prostate cancer xenografts, and the sensitizing effect was correlated to histone acetylation (Camphausen et al., 2004b) .
In another recently published study, rational drug design was used to synthesize a library of HDAC inhibitors in an attempt to develop analogues with potential for clinical application as radiation sensitizers (Jung et al., 2005) . The structure of TSA was used as a starting point to synthesize and screen over 60 analogues incorporating a urea backbone and a hydroxamic acid moiety (Jung et al., 2005) . Analysis of the HDAC inhibition activity of the analogues identified six compounds that exhibited activity in the nanomolar range and were comparable to TSA and SAHA. These were then analysed for radiation sensitizing properties using clonogenic survival as an end point. The findings indicated that the analogues enhanced g-radiationinduced cytotoxicity in a cell-type-specific manner (Jung et al., 2005) . Although this study was limited to the use of a few cancer cell types and mechanisms by which the HDAC inhibitors enhanced radiation sensitivity were not investigated, it does represent steps in the right direction and the findings warrant further investigation of these hydroxamic analogues as potential radiation sensitizers. More generally, this study introduces the concept of designing HDAC inhibitors that are cell or HDAC isoform-specific and optimized for their radiation sensitizing properties, which would provide advantageous molecules for clinical translation.
Conclusion
A number of HDAC inhibitors are currently being investigated in clinical trials as potential cancer therapeutics. They induce numerous anticancer effects such as cell-cycle and growth arrest, differentiation and in certain cases apoptosis. The HDAC inhibitors that are in clinical trials interact with both class I and class II HDACs and effect varying responses in different cell types and biological settings. At this stage, we have a limited understanding of the precise mechanisms of action of HDAC inhibitors. This is to be expected as our knowledge of the functions of the different HDAC isotypes is also not complete. However, it is becoming apparent that there are differences and individual HDAC isoforms are emerging as potential therapeutic targets. Therefore, it is anticipated that much research will focus on identifying the functions of different HDACs and on the development of isoform-specific HDAC inhibitors. It will be interesting to see whether isotype-specific inhibitors can be synthesized and whether inhibition of specific HDACs would offer a therapeutic advantage compared to the current nonspecific molecules.
HDAC inhibitors can also augment the effects of other cytotoxic modalities such as chemotherapeutic drugs, UV and ionizing radiation. Establishing clinically relevant combinations of HDAC inhibitors and conventional cancer therapies is a research priority. In this context, it is becoming evident that the varying functions of different HDAC isotypes are also important and this has been extensively documented in the case of combinations of HDAC inhibitors and ionizing radiation. Although an attempt has been made to synthesize molecules that are optimized for their radiation sensitizing properties, the analogues in the library examined to date are based on the structure of TSA and therefore, not target specific. As our understanding of the mechanisms by which inhibition of HDACs enhance the radiation sensitivity of cells increases, so will the ability to improve the design of potential radiosensitizing HDAC inhibitors. Given the level of interest in epigenetic processes it is easy to foresee that our understanding of HATs, HDACs and HDAC inhibitors will expand. The expectation is that this will translate into further development of HDAC inhibitors that are effective therapeutics for cancer, either alone or in combination with other therapeutic modalities.
